Proteasomal Inhibition for Patients With Mis-sense Mutated Dysferlin
Dysferlin is a protein with an important role in the repair of muscle surface membranes. Mutations in dysferlin cause different forms of muscular dystrophies. Dysferlinopathies are inherited in an autosomal recessive manner, and many patients with this disease harbor mis-sense mutations in at least one of their two pathogenic DYSF alleles. These patients have significantly reduced or absent dysferlin levels in skeletal muscle, suggesting that dysferlin encoded by mis-sense alleles is rapidly degraded by the cell's quality-control system. In a series of in-vitro experiments we showed that mis-sense mutated dysferlin can be salvaged from degradation by proteasomal inhibition. This resulted in an increase of functional dysferlin protein and a subsequent repair of plasma membranes of cultured patient-derived muscle cells. In this proof-of-concept study we would like to test wether proteasomal inhibition can salvage mis-sense mutated dysferlin in patients harboring certain dysferlin mis-sense mutations.
|Study Design:||Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Proteasomal Inhibition for Patients With Mis-sense Mutated Dysferlin|
- Dysferlin protein expression levels change from baseline over 5 days assessed by repeated biopsies and blood draws in skeletal muscle and in blood monocytes following administration of a single dose of Bortezomib. [ Time Frame: repeated needle muscle biopsies over a five day period ] [ Designated as safety issue: No ]Repeated needle muscle biopsies and blood draws will be performed after administration of a single dose of Bortezomib (Velcade) to assess dysferlin protein expression in skeletal muscle and in blood monocytes over a five day period.
|Study Start Date:||December 2012|
|Estimated Study Completion Date:||December 2016|
|Estimated Primary Completion Date:||December 2016 (Final data collection date for primary outcome measure)|
Experimental: Bortezomib (Velcade®)
This study tests whether salvage of mis-sense mutated dysferlin through proteasomal inhibition seen in cultured muscle cells can be translated into patients harboring dysferlin mis-sense mutations. The proteasomal inhibitor Bortezomib (Velcade®) is already approved as a medication for the treatment of multiple myeloma in Switzerland and in other countries.
Following an administration of a single dose of Bortezomib repeated needle muscle biopsies and blood draws will be performed to assess dysferlin levels in skeletal muscle and blood monocytes over a five day period.
Other Name: Velcade®
Please refer to this study by its ClinicalTrials.gov identifier: NCT01863004
|Contact: Michael Sinnreich, Prof. Dr. med. Dr. phil.||0041-61-55 ext email@example.com|
|Neuromuskuläres Zentrum, Universitätsspital Basel||Recruiting|
|Basel, Switzerland, 4031|
|Contact: Michael Sinnreich, Prof. Dr. med. Dr. phil. 0041-61-265 41 30 firstname.lastname@example.org|
|Principal Investigator: Michael Sinnreich, Prof. Dr. med. Dr. phil.|
|Sub-Investigator: Bilal A. Azakir, PhD|
|Principal Investigator:||Michael Sinnreich, Prof. Dr. med. Dr. phil.||Sponsor-Investigator, Neuromuscular Center, Neurology Clinic, University Hospital Basel, Switzerland|